Introduction {#Sec1}
============

It is estimated that 48 million couples were affected by infertility in 2010, and there has not been any significant improvement in infertility levels between 1990 and 2010 \[[@CR1]--[@CR3]\]. In the USA, 12% of women aged 15--44 have impaired fecundity. Increasingly, more couples rely on assisted reproductive technologies (ART) to get pregnant and have children, and in the USA, 231,936 ART cycles were performed in 2015 \[[@CR4]\].

A significant proportion of infertility cases are due to genetic defects. Male infertility accounts for 50% of infertility cases \[[@CR5]\], with known genetic factors accounting for 15--30% of male infertility \[[@CR6]\]. Chromosomal alterations \[[@CR7]\], inversions \[[@CR8]\], translocations \[[@CR9]\], Y chromosome microdeletions \[[@CR10]\], and gene mutations (for example single-nucleotide variants (SNVs) in *CFTR* \[[@CR11]\]) are the main genetic variants causing male infertility. In females, infertility is a more heterogeneous condition. While genetics clearly play a role, these effects are mostly polygenic, making it difficult to define a single genetic cause. The two most common female factor conditions, ovulatory dysfunction (25%) and endometriosis (15%), have familial predisposition, suggesting a genetic basis \[[@CR12]\]. In addition, sex chromosome alterations \[[@CR13]\] and several single gene mutations have been described impacting female fertility \[[@CR14], [@CR15]\], causing conditions like hypogonadotropic hypogonadism, premature ovarian insufficiency, endometriosis, and polycystic ovarian syndrome (reviewed in \[[@CR12]\]).

Traditionally, several assays are needed to make a definitive genetic diagnosis of infertility, which makes the process expensive and slow. For example, in males, a variety of techniques are necessary for analysis of genetics: sex chromosome aneuploidies are detected by cytogenetic tests like karyotyping; Y chromosome microdeletions are detected by polymerase chain reaction (PCR)-based methods; and *CFTR* mutations are detected by Sanger DNA sequencing. However, a shotgun approach in which all genetic tests are ordered for all patients is not recommended because cost is prohibitive \[[@CR16]\]. In females, success rates vary depending on many factors with age being the most important. An infertility evaluation includes very diverse tests including blood and urine hormone levels, imaging, and for women with unexplained infertility issues, genetic tests like karyotyping or DNA sequencing of selected genes.

Next-generation sequencing (NGS) permits the simultaneous interrogation of multiple disease-causing variants in many genes, allowing expanded genetic diagnostics to be routinely used in medical practice. This is already a reality in other medical fields, like oncology \[[@CR17]\] and heart disease \[[@CR18]\], where panel testing allows for the most comprehensive assessment of genetic etiologies. NGS is also very cost-effective as it allows for the detection of very different types of variants (for example, SNVs, small indels, large Y chromosome deletions, and sex chromosome aneuploidies) by using a single test in combination with multiple bioinformatics algorithms to process these diverse data. Here, we present the development of an NGS panel and bioinformatics pipeline for the detection of genetic variants with direct impact on female and male infertility. We also present a cost comparative analysis of current approaches in comparison with the NGS test.

Materials and methods {#Sec2}
=====================

Subjects and samples {#Sec3}
--------------------

Samples of genomic DNA with previously identified variants in the genes interrogated by the sequencing panel were obtained as purified DNA from the Human Genetic Cell Repository (National Institute of General Medical Sciences) at the Coriell Institute for Medical Research (Camden, NJ) or the Indiana Biobank (Indianapolis, IN) or extracted from saliva samples collected by DNAsimple (Philadelphia, PA). All samples submitted to our diagnostics laboratory as saliva were manually extracted using the Qiagen QIAamp Mini Kits following the manufacturer's instructions. DNA was quantified using Quant-iT Picogreen dsDNA Assay Kit (Life Sciences) and a Varioskan LUX (Thermo Scientific). Supplementary Table [S1](#MOESM1){ref-type="media"} describes all samples used in this study, with biorepository numbers, as well as their previous characterization results and rationale for inclusion. All samples presented here are de-identified (HHS 45 CFR part 46.101(b)(4)). IRB approval to handle de-identified samples was obtained through ASPIRE (Santee, CA), protocol IRB-R-003.

Fertility panel description {#Sec4}
---------------------------

A targeted next-generation sequencing panel consisting of 87 genes related to infertility disorders was created (Supplementary Table [S2](#MOESM1){ref-type="media"}). Genes relevant to disease phenotype were included based on relationships described in Online Mendelian Inheritance in Man (OMIM), Human Phenotype Ontology (HPO), GeneReviews, and primary literature. The panel included all coding exons, splice sites, promoter regions, 5′ untranslated regions (UTRs), and 3′ UTRs for each of the genes. Clinically relevant noncoding (intronic) regions that contained previously described pathogenic variants, as reported in ClinVar NIH database, were also included. The total size of the gene panel is 1,444,982 bp. In addition, selected regions from the Y chromosome (928,649 bp) were included to allow for the detection of Y chromosome microdeletions. Finally, the panel also includes 188 genes that we considered "research" genes, with links to infertility and which we wanted to follow for research purposes (Supplementary Table [S3](#MOESM1){ref-type="media"}).

Next-generation DNA sequencing {#Sec5}
------------------------------

All laboratory procedures were performed in a Clinical Laboratory Improvement Amendments (CLIA) laboratory. DNA samples were prepared for sequencing using HyperPlus Library Preparation Kit (Roche, Indianapolis, IN) and sequenced on a NextSeq500 (Illumina, San Diego, CA), following the manufacturer's instructions. A detailed sequencing protocol is provided in [Supplementary Methods](#MOESM2){ref-type="media"} section.

Variant identification and classification {#Sec6}
-----------------------------------------

All bioinformatics algorithms were implemented within the Elements^™^ platform (Phosphorus, New York, NY). FASTQ files were produced from each sequencing run and processed using the germline calling pipeline (version 2.03.01.30066) in DRAGEN (Edico Genome, San Diego, CA). Variants identified by NGS were confirmed by an orthogonal method (microarrays or Sanger sequencing). After confirmation, each variant was classified as pathogenic, likely pathogenic, variant of unknown significance (VUS), likely benign, or benign, following the American College of Medical Genetics (ACMG) guidelines \[[@CR19]\].

Orthogonal confirmation {#Sec7}
-----------------------

A custom Affymetrix Axiom array was used to confirm all the reportable variants including SNVs, indels, CNVs, Y chromosome microdeletions, and sex chromosome aneuploidies. Microarrays were processed following the manufacturer's instructions. To confirm variants not included in the microarray, Sanger sequencing was used. Orthogonal analysis was also performed for cases when there was discrepancy between expected and received NGS results. If both NGS and confirmatory results agreed, the results were counted as concordant. Detailed protocols are described in the [Supplementary Methods](#MOESM2){ref-type="media"} section.

FMR1 testing {#Sec8}
------------

*FMR1* testing was performed with 120 ng genomic DNA per sample and the AmplideX PCR CE *FMR1* kit (Asuragen, Austin, TX), following the manufacturer's instructions. PCR products were separated in a 3500XL capillary electrophoresis system (Applied Biosystems, Foster City, CA) using conditions described in the *FMR1* kit manual.

Results {#Sec9}
=======

Gene panel design {#Sec10}
-----------------

To maximize the clinical impact of our comprehensive infertility genetic test, we focused only on genes with demonstrated impact on infertility phenotype. Genes were classified as "diagnostic" when variants in them were reported to cause infertility across multiple populations, as supported by multiple publications from different laboratories, demonstrating a direct relationship with infertility. Genes were classified as "informative" when variants in them were reported to be associated with infertility, but the causality link has not been unequivocally established. For male infertility, the panel includes Y chromosome microdeletions, *CFTR* mutations, and sex chromosome aneuploidies \[[@CR6]\]. For female infertility, the panel includes sex chromosome aneuploidies and genes in which variants have been associated with recurrent pregnancy loss caused by thrombophilia, primary ovarian insufficiency, polycystic ovary syndrome, and ovarian hyperstimulation syndrome. The gene list, as well as the rationale used for their selection, is shown in Fig. [1](#Fig1){ref-type="fig"} and Supplementary Table [S2](#MOESM1){ref-type="media"}. Figure [2](#Fig2){ref-type="fig"} describes the laboratory and analysis workflow.Fig. 1Description of the NGS panel by gene content, organized by the main infertility indications. Genes classified as "diagnostic" are shown in standard font, and genes classified as "informative" are shown in *italic font*Fig. 2**a** Outline of our NGS test. A DNA sample (saliva or blood) is sequenced by NGS and processed by our custom bioinformatics pipeline. Y chromosome microdeletions, sex chromosome aneuploidies, *CFTR* IVS8-5T polymorphism, indels, and SNVs are called. Variants are interpreted by expert curators and a medical report is generated. In parallel, *FMR1* testing is performed using PCR and capillary electrophoresis, and results are incorporated into the medical report. **b** Example of Y chromosome microdeletion called in sample NA18337. **c** Example of IVS8-5T tract detection in sample NA19108, heterozygous for 5T/7T

Analytical and clinical validation {#Sec11}
----------------------------------

To validate panel performance and determine analytical sensitivity, specificity, and accuracy, we sequenced 24 samples from the 1000 Genomes (1000G) project \[[@CR20]\] for which the location of SNVs and indels are known (Supplementary Table [S1](#MOESM1){ref-type="media"}). Representative sequencing quality control statistics are shown in Supplementary Table [S4](#MOESM1){ref-type="media"}. NGS results from these validation samples were compared to known 1000G variants (Table [1](#Tab1){ref-type="table"}). Microarray analysis and/or Sanger sequencing was performed to assess the discrepancies of SNVs/indels between results produced by the NGS panel and previously known 1000G data. Analytical sensitivity of the test was \> 99% for SNVs and \> 91% for indels, and specificity was \> 99% for both SNVs and indels. Final accuracy for SNVs and indels was 99.98 and 99.42%, respectively.Table 1Performance characteristics of the NGS test. *PPV*, positive predictive value; *NPV*, negative predictive value; *CNV*, copy number variantVariant typeTrue positivesTrue negativesFalse positivesFalse negativessnp4578257,918240Indel1372106013Variant typeAccuracySensitivitySpecificityPPVNPVsnp99.98%99.13%99.98%99.96%99.98%Indel99.42%91.33%99.39%100.00%99.39%Batch typeConcordantDiscordantConcordanceIntra-batch5881797.19%Inter-batch4272893.85%

To determine clinical sensitivity in the detection of CNVs, sex chromosome aneuploidies and Y chromosome microdeletions, we used 34 samples with 38 known variants (Supplementary Table [S1](#MOESM1){ref-type="media"}). The set of variants previously known for these samples is limited, so specificity could not be assessed. The analysis correctly detected 3/3 CNVs, 19/19 sex chromosome aneuploidies, and 15/16 Y chromosome microdeletions (Supplementary Tables [S5](#MOESM1){ref-type="media"} and [S6](#MOESM1){ref-type="media"}, Table [1](#Tab1){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). In three cases (NA20435, NA18333, and NA22031), Y chromosome microdeletions of smaller size were found by NGS when compared to previously known data (Supplementary Table [S6](#MOESM1){ref-type="media"}); however, microarray analysis confirmed the previously reported microdeletion size. In one case (NA20434), NGS data located the microdeletion 1.17 Mbp downstream of the previously known location, and microarray analysis confirmed NGS result. Sample NA12662 has a sex chromosome aneuploidy (duplication of X chromosome) and a Y chromosome microdeletion ((22769319-27097245)x0). The sex chromosome aneuploidy was identified, but the Y chromosome microdeletion was missed. Thus, clinical sensitivity for sex chromosome aneuploidies and CNVs is 100% (22/22), and for Y chromosome microdeletions, it is 93.75% (15/16).

Next, 11 DNA samples with 17 known SNVs/indels were processed (Table [2](#Tab2){ref-type="table"}). Known variants were confirmed in 16/17 cases. Sample NA02795 was reported with a pathogenic variant *GALT* c.130G\>A; p.Val44Met. However, this variant was not identified by NGS and Sanger sequencing did not detect it either; therefore, based on NGS and Sanger sequencing concordance, we did not count this case against the sensitivity. Thus, clinical sensitivity for SNVs/indels by our assay was 100%.Table 2Clinical sensitivity was determined by sequencing SNVs/indels of known variantsSamplePreviously reportedNGS test callNA11763*GALT* c.591A\>G; p.Gln188Arg*GALT* NM_000155.3:c.563A\>G; p.Gln188ArgNA11763*GALT* c.1025C\>T; p.Arg333Trp*GALT* NM_000155.3:c.997C\>T; p.Arg333TrpNA14899*F5* c.1691G\>A; p.Arg506Gln (homozygous)*F5* NM_000130.4:c.1691G\>A; p.Arg506GlnIndianaBiobank02*SERPINC1* c.1148_1149delTC; p.Leu383Profs\*10*SERPINC1* NM_000488.3:c.1148_1149delTC; p.Leu383Profs\*10NA00422*GALT* c.563A\>G; p.Gln188Arg*GALT* NM_000155.3:c.563A\>G; p.Gln188ArgNA00422*GALT* c.1030C\>A; p.Gln344Lys*GALT* NM_000155.3:c.1030C\>A; p.Gln344LysNA02795*GALT* c.425T\>A; p.Met142Lys*GALT* NM_000155.3:c.425T\>A; p.Met142LysNA02795*GALT* c.130G\>A; p.Val44MetNoneDNAsimple01*CFTR* c.1584G\>A; p.Glu528=*CFTR* NM_000492.3:c.1584G\>A; p.Glu528=NA02796*GALT* c.512T\>C; p.Phe171Ser*GALT* NM_000155.3:c.512T\>C; p.Phe171SerNA02796*GALT* c.404C\>T; p.Ser135Leu*GALT* NM_000155.3:c.404C\>T; p.Ser135LeuNA16643\**F5* c.1691G\>A; p.Arg506Gln*F5* NM_000130.4:c.1601G\>A; p.Arg534GlnNA17431*GALT* c.591A\>G; p.Gln188Arg*GALT* NM_000155.3:c.563A\>G; p.Gln188ArgNA17431*GALT* c.612T\>C; p.Leu195Pro*GALT* NM_000155.3:c.584T\>C; p.Leu195ProNA16000*MTHFR* c.677C\>T; p.Ala222Val*MTHFR* NM_005957.1:c.677C\>T; p.Ala222ValNA16000*F2* c.20210G\>A (homozygous)*F2* NM_000506.4:c.\*97G\>ADNAsimple02*F2* c.20210G\>A*F2* NM_000506.4:c.\*97G\>A\*The official designation of F5 c.1691G\>A is NM_000130.4:c.1601G\>A; NP_000121.2:p.Arg534Gln

CFTR intron 8 poly dT (IVS8-5T) {#Sec12}
-------------------------------

Varied lengths of a thymidine (T)-tract (5, 7, or 9T) are found in front of the splice-acceptor site of intron 8 of the *CFTR* gene in males with congenital bilateral absence of the vas deferens \[[@CR21]\]. The length correlates with the efficiency of exon 9 splicing. This polymorphism is detected clinically by allele-specific multiplex PCR \[[@CR22]\]. In order to determine sensitivity of the NGS panel, we analyzed 72 samples from the 1000G project. When 1000G data was used as reference, the NGS panel correctly detected the IVS8 alleles in 67/72 cases, and for the 5 discrepant cases, Sanger sequencing demonstrated that the NGS panel call was the correct one (Supplementary Table [S7](#MOESM1){ref-type="media"}). Therefore, our assay had 100% sensitivity to detect the *CFTR* IVS8-5T allele.

FMR1 testing {#Sec13}
------------

CGG triplet expansions are known to cause fragile X syndrome, and alleles in the pre-mutation range have been associated with increased risk for premature ovarian failure \[[@CR23]\]. Current NGS protocols based on hybridization enrichment for targeted panels do not accurately quantify the number of repeats. Therefore, to complement the NGS panel with *FMR1* analysis, we used an already available protocol based on PCR amplification and capillary electrophoresis detection of CGG repeats \[[@CR24]\]. Test sensitivity was determined by analysis of 26 samples harboring different CGG repeat expansions (Supplementary Table [S8](#MOESM1){ref-type="media"}). We correctly identified all alleles previously classified as "mutation" (\> 200 CGG repeats), "pre-mutation" (55 to 199 CGG repeats), and "normal" (\< 45 CGG repeats). However, the assay misclassified one allele in the "intermediate" range (between 45 and 54 CGG repeats) as "pre-mutation" (NA20236, 53 vs 55 CGG repeats, Supplementary Table [S8](#MOESM1){ref-type="media"}). Given that the rate of expansions of intermediate alleles is not well understood, testing at-risk relatives of individuals with an intermediate allele may determine the stability of the allele in the family \[[@CR25]\].

Cost analysis {#Sec14}
-------------

Currently, after semen analysis, in cases where severe abnormal semen analysis is observed, genetic testing for variants associated with male infertility is performed with multiple assays. For example, *CFTR* IVS8-5T is detected by allele-specific multiplex PCR \[[@CR22]\], Y chromosome microdeletions are detected by PCR of sequence-tagged sites \[[@CR26]\], and sex chromosome aneuploidies are detected by traditional karyotyping or microarrays \[[@CR27]\]. NGS can detect all these variants using a single test. In order to determine the economic impact, we performed a cost analysis for the male fertility panel, using average pricing available from reference laboratories performing these assays (Table [3](#Tab3){ref-type="table"} and Supplementary Table [S9](#MOESM1){ref-type="media"}). Overall, the savings to providers could be as much as \$2723 per case, \$3322 if performed by multiple assays vs \$599 if performed by NGS, which translates in savings of \> 550%. Furthermore, NGS testing has a shorter turnaround time because there is no need to do reflex testing. The only exception may be cases with complex chromosomal rearrangements and mosaics or translocations/inversions that do not result in gain/loss of DNA and are, therefore, not captured by the NGS panel.Table 3Cost comparison between traditional diagnostic methods for male infertility and NGS diagnostic testVariantMethodologyCPT codeCost (\$US)CFTR IVS8 poly T tractMultiplex polymerase chain reaction, Sanger sequencing or NGS81,224396CFTR mutationsSanger sequencing of CFTR gene81,2231430Sex chromosome aneuploidiesKaryotype88,262946Y chromosome microdeletionPCR-based analysis of 14 different regions along the length of the Y chromosome81,403660Total cost:3322NGS infertility testNGS sequencing, includes confirmation with orthogonal methods (microarray or Sanger)81,224, 81,223, 88,262, 81,403599

Discussion {#Sec15}
==========

We present a comprehensive genetic test based on NGS that covers the main infertility indications \[[@CR6], [@CR12]\]: the female panel analyzes genes associated with increased risks for female infertility, including primary ovarian insufficiency, polycystic ovary syndrome, sex chromosome aneuploidy, ovarian hyperstimulation syndrome, and thrombophilia-related pregnancy loss (Fig. [1](#Fig1){ref-type="fig"}). The male panel includes Y chromosome microdeletions, congenital absence of the vas deferens, sex chromosome aneuploidy, and other causes of male factor infertility (Fig. [1](#Fig1){ref-type="fig"}).

From a clinical care perspective, this NGS test has the ability to influence key decisions in patient management following infertility diagnosis. In the case of female infertility patients, a complement or earlier diagnosis of predisposition to severe diminished ovarian response or premature ovarian failure may help providers to better guide patients to gamete cryopreservation in anticipation of future pregnancies. For patients found to have a definitive diagnosis of polycystic ovary syndrome, it has been shown that patients who receive a gonadotropin-releasing hormone antagonist protocol undergoing controlled ovarian stimulation experience reduced risk of ovarian hyperstimulation syndrome \[[@CR28]\].

For male infertility patients, it is a routine for IVF laboratories or reproductive urologists to perform semen analysis for sperm count, motility, and morphology. For those men with results indicative of severe oligospermia or azoospermia, it is a routine to reflex to genetic tests to help explain etiology and guide treatment. Depending on the nature of the mutations, providers are able to better determine whether male patients are candidates for surgical retrieval of sperm \[[@CR29]\]. Reduced cost and faster turnaround time in genetic analysis will help patients reach the proper treatment more efficiently.

Genetic analysis is currently performed using many different platforms: SNVs and indels are detected by Sanger sequencing or NGS, sex chromosome aneuploidies by karyotyping or microarrays, Y chromosome microdeletions by multiplex PCR of sequence tags, and *CFTR* intron 8 polymorphism by allele-specific multiplex PCR. NGS allows for the detection of these different variants using a single platform with excellent sensitivity and specificity. Out of 127 different events, the NGS panel complemented with orthogonal confirmation methods accurately detected almost all of them: 17/17 SNVs/indels, 3/3 CNVs, 19/19 sex chromosome aneuploidies, 15/16 Y chromosome microdeletions, and 72/72 *CFTR* IVS8 polymorphic sites (5 of them IVS8-5T). In three Y chromosome microdeletion cases, the NGS panel identified microdeletions of smaller size; however, an analysis using microarrays confirmed the previously known size in all three cases. The NGS panel, thus, identified accurately most Y chromosome microdeletions (one Y chromosome microdeletion was missed), but orthogonal methods are required to confirm the microdeletion size. In summary, overall clinical sensitivity for all variants is 99.21% (126/127).

Our study has several limitations. Sample size is limited, and even though we processed samples representing all types of variants, the final number of samples in each group is small. For example, we only processed three clinical samples containing CNVs. Therefore, given limited sample size, performance characteristics must be interpreted with caution. In addition, this is a retrospective study, so it serves as a proof of concept, but a prospective study (currently ongoing at our center) will be needed to confirm our findings.

In its current form, the NGS panel cannot detect balanced translocations; therefore, it would miss reciprocal translocations and Robertsonian translocations, which are known to cause infertility in 0.9% of men \[[@CR9]\]. Furthermore, the NGS panel cannot detect complex chromosomal rearrangements like derivative chromosomes or mosaicism, even though these often involve gain or loss of DNA. We tested several samples with derivative chromosomes and mosaicism and the current NGS panel could not accurately assess these variants. For example, samples IndianaBiobank01 and NA21681 in Supplementary Table [S5](#MOESM1){ref-type="media"} contain a derivative X,Y chromosome and a 6,Y translocation, respectively, and both were missed. In these cases, a karyotype is needed, which could be used as reflex after the NGS test. We are currently investigating the possibility to incorporate detection of these abnormalities as part of this NGS test \[[@CR30]\].

Another limitation is the detection of *FMR1* variant caused by triplet CGG expansion, varying from 20 to \> 900 repeats. It is not possible to accurately identify triplet expansions by using PCR-enriched NGS. New methods involving PCR-free libraries allow diagnosis \[[@CR31]\], but it would require a parallel library preparation and sequencing reaction, significantly increasing cost. Therefore, currently, a separate PCR assay to determine *FMR1* mutation is needed to assess fragile-X mutation.

The direct consequence of using a single NGS assay instead of multiple diagnostic assays, each one detecting a class of DNA variants, is a potential reduction in cost and turnaround time required to make a definitive diagnosis, with savings that could be up to \$2723 per case (\$3322 for traditional methods vs \$599 for NGS testing). Integrating testing into a single assay simplifies test ordering and result tracking for the clinician and decreases cost to the patient by reducing the number of assays that need to be performed, analyzed, and reported.

Conclusions {#Sec16}
===========

We have developed a comprehensive genetic test for female and male infertility that achieves excellent clinical sensitivity, but at a fraction of the cost of traditional methods of testing, and a shorter turnaround time than current methods.
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